EMA Withdrawn: Nivolumab BMS (nivolumab) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

EMA withdrawn nivolumab (BMS) for non-small cell lung carcinoma; product withdrawal decision in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (Bristol-Myers Squibb Pharma EEIG) (nivolumab)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 30/11/2015